CRO providers division of Galapagos to be acquired by Charles River Laboratories Charles River Laboratories International, Inc. announced today that it provides entered right into a definitive contract to acquire the CRO providers division of Galapagos NV , which include both BioFocus and Argenta. These continuing businesses are global leaders in integrated medication discovery services, with a predominant focus on in vitro capabilities nettapotek . The acquisition shall position Charles River as a complete service, early-stage contract research firm , with integrated in vitro and in vivo capabilities from focus on discovery through preclinical advancement. James C. Foster, Chairman, President, and Chief Executive Officer of Charles River Laboratories, commented, ‘The acquisition of Argenta and BioFocus can be precisely in line with our strategy to create a broader portfolio of important products and services to aid the medication discovery and development continuum, and the raising virtualization of the biopharmaceutical sector.
CSIRO symptoms global licensing agreement for Reversible Addition-Fragmentation chain Transfer technology CSIRO has signed a worldwide licensing agreement for its patented RAFT technology. Reversible Addition-Fragmentation chain Transfer technology can be an elegant and powerful polymerisation process that has provided rise to a new branch of polymer chemistry. RAFT enables the advancement of highly complex molecules which you can use for an array of products. The technology is normally generating major improvements in the areas of coatings and paints currently, electroactive materials, fuel additives, biomaterials, polymer synthesis, personal care, medication delivery car and brokers elements.